🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety

Recruitingn/aAges 18 Years - 85 YearsAllTechnische Universität Dresden
NCT06126601 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Recent evidence suggests that postoperative hyperamylasemia (POH) is a predictor of morbidity after pancreatectomy. This is based on the assumption that pancreatitis after pancreatectomy (PPAP) is a major trigger for the development of complications and is indicated by hyperamylasemia. Standardized prospective analysis and correlation with other laboratory parameters, hasn't been performed to date. Therefore the overall study aims are: * To prospectively evaluate the incidence and assess the clinical value of biochemical changes for the postoperative course. * To confirm and improve the definition and classification of postpancreatectomy acute pancreatitis (PPAP) of the International Study Group of Pancreatic Surgery (ISGPS) and to provide knowledge for effective early management of complications.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * All patients undergoing pancreatic resection for malignant and benign disease with or without pancreatic anastomosis * Patients aged 18-85 years * Willingness to participate as demonstrated by giving a written informed consent. Exclusion Criteria: * Necrosectomy (endoscopic or open) for primary acute pancreatitis or within laparotomy * Age less than 18 years * Surgical drainage procedures without pancreatic resection (cystojejunostomy for pancreatic pseudocysts) * One-stage total pancreatectomy * Missing written consent
💊

What it tests

  • Pancreatectomy
📍

Where

1 site
University Hospital Dresden, Dept. Visceral, Thoracic and Vascular Surgery
Dresden, Germany
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy